NASDAQ:KITE - Kite Pharma Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $179.79 0.00 (0.00 %) (As of 12/10/2018 01:36 AM ET)Previous Close$179.79Today's Range$179.79 - $179.7952-Week Range$39.82 - $179.99VolumeN/AAverage Volume1.65 million shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL). Receive KITE News and Ratings via Email Sign-up to receive the latest news and ratings for KITE and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry N/A Sub-IndustryN/A SectorN/A Current SymbolNASDAQ:KITE Previous Symbol CUSIPN/A Webwww.kitepharma.com Phone+1-310-8249999 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees447 Outstanding SharesN/AMarket Cap$0.00 OptionableOptionable Kite Pharma (NASDAQ:KITE) Frequently Asked Questions What is Kite Pharma's stock symbol? Kite Pharma trades on the NASDAQ under the ticker symbol "KITE." How were Kite Pharma's earnings last quarter? Kite Pharma Inc (NASDAQ:KITE) announced its earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) EPS for the quarter, beating the consensus estimate of ($1.75) by $0.05. The biopharmaceutical company had revenue of $4.90 million for the quarter, compared to analysts' expectations of $5.74 million. The company's revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.54) earnings per share. View Kite Pharma's Earnings History. Has Kite Pharma been receiving favorable news coverage? Press coverage about KITE stock has trended somewhat positive recently, InfoTrie reports. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Kite Pharma earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. Who are Kite Pharma's key executives? Kite Pharma's management team includes the folowing people: Arie S. Belldegrun, Executive Chairman of the Board, President, Chief Executive Officer, FounderPaul L. Jenkinson, Chief Financial OfficerCynthia M. Butitta, Chief Operating OfficerDavid Chang M.D. Ph.D., Executive Vice President - Research and Development, Chief Medical OfficerHelen S. Kim, Executive Vice President - Business DevelopmentTimothy L. Moore, Executive Vice President - Technical OperationsChristine Cassiano, Senior Vice President - Corporate Communications and Investor Relations, Bio & Compensation - Jian Irish Ph.D., Senior Vice President - Supply Chain, Bio & Compensation - Jeffrey Wiezorek M.D., Senior Vice President - Clinical DevelopmentShawn Cline Tomasello, Chief Commercial Officer How do I buy shares of Kite Pharma? Shares of KITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Kite Pharma's stock price today? One share of KITE stock can currently be purchased for approximately $179.79. What is Kite Pharma's official website? The official website for Kite Pharma is http://www.kitepharma.com. How can I contact Kite Pharma? Kite Pharma's mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The biopharmaceutical company can be reached via phone at +1-310-8249999. MarketBeat Community Rating for Kite Pharma (NASDAQ KITE)Community Ranking: 3.4 out of 5 ( )Outperform Votes: 683 (Vote Outperform)Underperform Votes: 325 (Vote Underperform)Total Votes: 1,008MarketBeat's community ratings are surveys of what our community members think about Kite Pharma and other stocks. Vote "Outperform" if you believe KITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KITE will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2018 by MarketBeat.com StaffFeatured Article: How Does the Quiet Period Work?